Clinical trials of new drugs for Alzheimer disease

Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an anta...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of biomedical science Ročník 27; číslo 1; s. 18 - 13
Hlavní autoři:	Huang, Li-Kai, Chao, Shu-Ping, Hu, Chaur-Jong
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 06.01.2020 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Advertising executives Alzheimer disease Alzheimer's disease Amyloidosis Anti-Alzheimer's disease agents Anti-amyloid Anti-tau Aspartate Atrophy Biomarkers Biomedical and Life Sciences Biomedicine Brain Cholinesterase Cholinesterase inhibitors Clinical trials Clinical trials of drugs Cognitive ability Dementia Dementia disorders Disease control Diseases Drug therapy Drugs Glutamate receptors Hypotheses Immunotherapy Inflammation Magnetic resonance imaging Medical research Memory Metabolism N-methyl-D-aspartate N-Methyl-D-aspartic acid receptors Neurodegeneration Neurodegenerative diseases Neuroinflammation Neuroprotection Neurotransmitters Pathogenesis Peptides Pharmaceutical industry Product development Psychological symptoms Reason Review Signs and symptoms Tau protein Time Trends United States > US Neuroprotection Anti-tau Alzheimer disease Anti-amyloid Neuroinflammation Cognitive enhancement Clinical trials of drugs
ISSN:	1423-0127, 1021-7770, 1423-0127
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies. In ongoing clinical trials, researchers have developed and are testing several possible interventions aimed at various targets, including anti-amyloid and anti-tau interventions, neurotransmitter modification, anti-neuroinflammation and neuroprotection interventions, and cognitive enhancement, and interventions to relieve behavioral psychological symptoms. In this article, we present the current state of clinical trials for AD at clinicaltrials.gov . We reviewed the underlying mechanisms of these trials, tried to understand the reason why prior clinical trials failed, and analyzed the future trend of AD clinical trials.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ISSN:	1423-0127 1021-7770 1423-0127
DOI:	10.1186/s12929-019-0609-7